
    
      Primary Objective:

      â€¢ Evaluate the frequency of dose reductions in two different lenalidomide dose regimens.

      Secondary Objectives:

        -  Evaluate the efficacy of two different lenalidomide dose regimens in patients with
           multiple myeloma using the EBMT and IMWG criteria.

        -  Evaluate the duration of response of 15 mg Lenalidomide and 25 mg of Lenalidomide when
           used in combination with Low Dose Dexamethasone.

        -  Evaluate the safety of 15 mg and 25 mg of Lenalidomide regiments when in combination
           with dexamethasone.

        -  Explore blood and cellular levels of angiogenic factors, cytokines, and adhesion
           molecules.
    
  